^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Fallopian Tube Cancer

    2d
    Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers (clinicaltrials.gov)
    P1, N=42, Recruiting, National Cancer Institute (NCI) | Trial completion date: Jun 2026 --> Feb 2027 | Trial primary completion date: Jun 2026 --> Feb 2027
    Trial completion date • Trial primary completion date
    |
    BRAF (B-raf proto-oncogene) • BCL2L1 (BCL2-like 1)
    |
    Cotellic (cobimetinib) • pelcitoclax (APG-1252)
    2d
    Fluzoparib With or Without Bevacizumab for Neoadjuvant Therapy in Advanced Ovarian Cancer (clinicaltrials.gov)
    P2, N=105, Recruiting, Qilu Hospital of Shandong University
    New P2 trial • Combination therapy • Metastases
    |
    Avastin (bevacizumab) • carboplatin • paclitaxel • AiRuiYi (fluzoparib)
    5d
    Epacadostat Before Surgery in Treating Patients With Newly Diagnosed Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov)
    P1, N=17, Completed, National Cancer Institute (NCI) | Active, not recruiting --> Completed
    Trial completion • Surgery
    |
    IDO1 (Indoleamine 2,3-dioxygenase 1)
    |
    epacadostat (INCB024360)
    6d
    A Study of Lorigerlimab in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P2, N=60, Not yet recruiting, MacroGenics
    New P2 trial • Metastases
    |
    lorigerlimab (MGD019)
    7d
    Recurrence Rate and Associated Factors of Primary Fallopian Tube Carcinoma in the South of Vietnam. (PubMed, Gynecol Minim Invasive Ther)
    The overall recurrence rate of PFTC patients in Southern Vietnam was 17.0%. Appropriate follow-up strategies for patients with high-risk factors are needed for early detection and management of recurrence.
    Journal
    |
    MUC16 (Mucin 16, Cell Surface Associated)
    7d
    Fallopian tube carcinoma mimicking inguinal hernia: A case report with imaging and histological insights. (PubMed, Radiol Case Rep)
    The mechanism in this case involved increased mobility of the left adnexa after hysterectomy and tumor infiltration near the inguinal canal. This case highlights the importance of considering fallopian tube carcinoma as a differential diagnosis when evaluating inguinal hernias, particularly in high-risk patients.
    Journal
    |
    MUC16 (Mucin 16, Cell Surface Associated)
    |
    MUC16 elevation
    9d
    Lyell START: A Biomarker Screening Protocol for Participants With Solid Tumors (clinicaltrials.gov)
    P=N/A, N=250, Enrolling by invitation, Lyell Immunopharma, Inc. | Recruiting --> Enrolling by invitation
    Enrollment status
    |
    ROR1 (Receptor Tyrosine Kinase Like Orphan Receptor 1)
    9d
    MV-NIS Infected Mesenchymal Stem Cells in Treating Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer (clinicaltrials.gov)
    P1/2, N=34, Active, not recruiting, Mayo Clinic | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Mar 2024
    Trial completion date • Trial primary completion date
    |
    CD4 (CD4 Molecule)
    |
    MV-NIS
    12d
    A Study of CDX-585 in Patients With Advanced Malignancies (clinicaltrials.gov)
    P1, N=130, Active, not recruiting, Celldex Therapeutics | Recruiting --> Active, not recruiting | Trial completion date: Feb 2026 --> May 2025 | Trial primary completion date: Dec 2024 --> May 2025
    Enrollment closed • Trial completion date • Trial primary completion date • Metastases
    |
    CDX-585
    13d
    Analysis of real world FRα testing in ovarian, fallopian tube, and primary peritoneal cancers. (PubMed, Gynecol Oncol)
    Our results highlight a need for standardized protocols for FRα testing to ensure accurate biomarker evaluation across varied clinical settings. The heterogeneity in FRα expression, influenced by tumor histology and anatomical origin, warrant further investigation to optimize therapeutic outcomes.
    Journal • Real-world evidence • Real-world
    |
    FOLR1 ( Folate receptor alpha )
    |
    FOLR1 expression
    |
    VENTANA FOLR1 RxDx Assay
    |
    Elahere (mirvetuximab soravtansine-gynx)
    14d
    TORL123-002: CATALINA-2: a Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer. (clinicaltrials.gov)
    P2, N=230, Recruiting, TORL Biotherapeutics, LLC | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    CLDN6 (Claudin 6) • PROC (Protein C, Inactivator Of Coagulation Factors Va And VIIIa)
    |
    TORL-1-23 • Neulasta (pegfilgrastim)
    15d
    TAp73 and ΔTAp73 isoforms show cell-type specific distributions and alterations in cancer. (PubMed, Sci Rep)
    TAp73 was found in 17% of these tumours, with a random distribution and no association with clinicopathological features. These data indicate roles for ΔTAp73 in maintaining a non-proliferative state of undifferentiated squamous epithelial cells and for TAp73 in the production of differentiated multiciliated cells.
    Journal
    |
    TP53 (Tumor protein P53) • TP73 (Tumor Protein P73)
    19d
    Surgery for Ovarian Cancer After PARPi Therapy in Precision (clinicaltrials.gov)
    P1/2, N=33, Not yet recruiting, Shanghai Gynecologic Oncology Group | Initiation date: Oct 2024 --> Jan 2025
    Trial initiation date • Surgery
    |
    PD-L1 (Programmed death ligand 1)
    |
    Tyvyt (sintilimab)
    21d
    First in Human Study of IMGN151 in Recurrent Gynaecological Cancers (clinicaltrials.gov)
    P1, N=423, Recruiting, ImmunoGen, Inc. | N=227 --> 423
    Enrollment change
    |
    FOLR1 ( Folate receptor alpha )
    |
    opugotamig olatansine (IMGN-151)
    23d
    BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas (clinicaltrials.gov)
    P2, N=46, Active, not recruiting, Brown University | Trial completion date: Dec 2025 --> Jun 2025 | Trial primary completion date: Jun 2024 --> Mar 2025
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab)
    26d
    Case report: High grade serous fallopian tube carcinoma with rare NRG1 gene fusion presenting as widespread peritoneal carcinomatosis. (PubMed, Front Oncol)
    Twenty-five additional tumors were found to demonstrate NRG1 fusions, including 20 new genes partners that had not been previously identified in gynecologic carcinomas. Overall, NRG1 fusion events are rare in ovarian, fallopian tube, and primary peritoneal carcinomas, but they may carry diagnostic significance in the context of borderline/low grade serous tumors, which demonstrated exclusively CLU::NRG1 fusions, and could have important predictive implications for response to ERBB/ERBB2/ERBB3-directed therapies.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3) • NRG1 (Neuregulin 1)
    |
    NRG1 fusion • NRG1 fusion
    27d
    CA116-001: A Study of MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (clinicaltrials.gov)
    P2, N=90, Active, not recruiting, Bristol-Myers Squibb | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    FOLR1 ( Folate receptor alpha )
    |
    paclitaxel • pegylated liposomal doxorubicin • topotecan • farletuzumab ecteribulin (MORAb-202)
    27d
    Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for the Treatment of Patients With Stage III or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, FAROUT Trial (clinicaltrials.gov)
    P2, N=78, Recruiting, Mayo Clinic | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    29d
    Pembrolizumab, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (clinicaltrials.gov)
    P2, N=31, Active, not recruiting, M.D. Anderson Cancer Center | Completed --> Active, not recruiting | Trial completion date: Jul 2024 --> Jul 2025 | Trial primary completion date: Jul 2024 --> Jul 2025
    Enrollment closed • Trial completion date • Trial primary completion date • Combination therapy
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • carboplatin • paclitaxel
    29d
    Study of Maplirpacept (PF-07901801) in Combination With PLD in Patients With Platinum-Resistant Ovarian Cancer (clinicaltrials.gov)
    P1/2, N=10, Terminated, Pfizer | Phase classification: P2 --> P1/2
    Phase classification • Combination therapy
    |
    pegylated liposomal doxorubicin • maplirpacept (TTI-622)
    29d
    MIRASOL: A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression (clinicaltrials.gov)
    P3, N=453, Completed, ImmunoGen, Inc. | Active, not recruiting --> Completed
    Trial completion • Metastases
    |
    FOLR1 ( Folate receptor alpha )
    |
    FOLR1 expression
    |
    paclitaxel • pegylated liposomal doxorubicin • Elahere (mirvetuximab soravtansine-gynx) • topotecan
    29d
    Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation (clinicaltrials.gov)
    P2, N=40, Completed, Roswell Park Cancer Institute | Active, not recruiting --> Completed
    Trial completion • Combination therapy
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
    |
    BRCA2 mutation • BRCA1 mutation
    |
    Lynparza (olaparib) • Imfinzi (durvalumab) • Imjudo (tremelimumab)
    1m
    Concurrent High-Grade Serous Carcinoma with Mucinous Differentiation and Ectopic Complete Molar Pregnancy of the Fallopian Tube: A Case Report. (PubMed, Ann Clin Lab Sci)
    This report emphasizes the crucial role of meticulous sampling and histopathologic examination of the fallopian tube, including the fimbriae, in all salpingectomy specimens. Furthermore, the case highlights the broad spectrum of morphologies encountered in HGSC, including mucinous differentiation. HGSC should be in the differential diagnosis when encountering mucin-producing high-grade carcinoma.
    Journal
    |
    TP53 (Tumor protein P53) • FOLR1 ( Folate receptor alpha )
    |
    TP53 mutation • TP53 R273H
    1m
    The Efficacy and Safety of Folate Receptor α-Targeted Antibody-Drug Conjugate Therapy in Patients With High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers: A Systematic Review and Meta-Analysis. (PubMed, Cancer Med)
    FRα-targeting ADCs, including MIRV, demonstrated definite efficacy and good safety as novel choices for second-line and beyond treatment of advanced or recurrent ovarian cancer. Patients with high FRα expression showed ORR and PFS benefits similar to those in the overall cohort.
    Clinical • Retrospective data • Review • Journal
    |
    FOLR1 ( Folate receptor alpha )
    |
    FOLR1 expression
    |
    Halaven (eribulin mesylate) • Elahere (mirvetuximab soravtansine-gynx) • luveltamab tazevibulin (STRO-002) • farletuzumab ecteribulin (MORAb-202)
    1m
    PERCEPTION: Study of Pembrolizumab Combination With Chemotherapy in Platinum-sensitive Recurrent Low-grade Serous Ovarian Cancer (clinicaltrials.gov)
    P2, N=33, Recruiting, North Eastern German Society of Gynaecological Oncology | Trial primary completion date: Nov 2024 --> Apr 2025
    Trial primary completion date
    |
    Keytruda (pembrolizumab) • carboplatin
    1m
    CATALINA-2: a Phase 2 Study of TORL-1-23 in Advanced Ovarian Cancer. (clinicaltrials.gov)
    P2, N=230, Not yet recruiting, TORL Biotherapeutics, LLC
    New P2 trial • Metastases
    |
    CLDN6 (Claudin 6) • PROC (Protein C, Inactivator Of Coagulation Factors Va And VIIIa)
    |
    CLDN6 expression
    |
    TORL-1-23 • Neulasta (pegfilgrastim)
    1m
    Nivolumab with or Without Ipilimumab in Treating Patients with Recurrent or High Grade Gynecologic Cancer with Metastatic Peritoneal Carcinomatosis (clinicaltrials.gov)
    P1, N=26, Completed, M.D. Anderson Cancer Center | Active, not recruiting --> Completed | Trial completion date: Apr 2025 --> Nov 2024 | Trial primary completion date: Apr 2025 --> Nov 2024
    Trial completion • Trial completion date • Trial primary completion date • Metastases
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab)
    1m
    N-Plus: A Phase II Randomized, Open Label Non-inferiority Study of NiraParib Maintenance After 3 vs. 6 Cycles of Platinum-based Chemotherapy in completeLy debUlked Advanced HRDpositive High-grade Ovarian Cancer patientS in First Line Therapy (clinicaltrials.gov)
    P2, N=640, Recruiting, North Eastern German Society of Gynaecological Oncology | Not yet recruiting --> Recruiting
    Enrollment open • Head-to-Head • Metastases
    |
    BRCA (Breast cancer early onset)
    |
    carboplatin • Zejula (niraparib)
    1m
    MAMOC: Rucaparib MAintenance After Bevacizumab Maintenance Following Carboplatin Based First Line Chemotherapy in Ovarian Cancer Patients (clinicaltrials.gov)
    P3, N=42, Completed, North Eastern German Society of Gynaecological Oncology | Active, not recruiting --> Completed | N=190 --> 42 | Trial completion date: Jan 2025 --> Jul 2024
    Trial completion • Enrollment change • Trial completion date
    |
    Avastin (bevacizumab) • carboplatin • Rubraca (rucaparib)
    1m
    Validation of a Homologous Recombination Deficiency (HRD) Assay for Use in Combination with Comprehensive Genomic Profiling (CGP) Testing (AMP 2024)
    The TruSight Oncology 500 comprehensive solid tumor next-generation sequencing panel with HRD assay demonstrated a high degree of sensitivity and specificity for deployment in a clinical setting.
    Combination therapy • BRCA Biomarker • PARP Biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • HRD (Homologous Recombination Deficiency)
    |
    HRD
    |
    Myriad myChoice® CDx • TruSight Oncology 500 Assay • TruSight Oncology 500 HRD Assay
    1m
    Comparison of Ovarian Tumor Homologous Recombination Deficiency (HRD) Status Generated from the Illumina TruSight Oncology 500 (TSO500) High-Throughput HRD Assay to the Myriad myChoice CDx Assay (AMP 2024)
    The FDA (US Food and Drug Administration) has approved olaparib as a front-line maintenance therapy in combination with bevacizumab for patients with newly diagnosed advanced ovarian, fallopian tube, or primary peritoneal cancer with HRD+ status. We have demonstrated that the TSO500-HRD assay can accurately determine HRD status in ovarian tumors.
    BRCA Biomarker • PARP Biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • HRD (Homologous Recombination Deficiency)
    |
    BRCA2 mutation • BRCA1 mutation • HRD
    |
    Myriad myChoice® CDx • TruSight Oncology 500 Assay • TruSight Oncology 500 HRD Assay
    |
    Avastin (bevacizumab) • Lynparza (olaparib)
    1m
    SGNB7H4V-001: A Study of SGN-B7H4V in Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=572, Recruiting, Seagen Inc. | N=430 --> 572 | Trial completion date: Jan 2027 --> Nov 2027 | Trial primary completion date: Jun 2025 --> Nov 2027
    Enrollment change • Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HR positive • HER-2 negative • PTEN mutation + HR positive
    |
    Keytruda (pembrolizumab) • felmetatug vedotin (PF-08046048)
    1m
    A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine (clinicaltrials.gov)
    P3, N=110, Not yet recruiting, AbbVie
    New P3 trial
    |
    Elahere (mirvetuximab soravtansine-gynx)
    1m
    TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=50, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Oct 2024 --> Oct 2025
    Trial completion date
    |
    BRAF (B-raf proto-oncogene)
    |
    Avastin (bevacizumab) • sapanisertib (CB-228) • Aybintio (bevacizumab biosimilar) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn)
    1m
    Ivonescimab (AK112) plus paclitaxel and carboplatin in frontline neoadjuvant therapy of advanced ovarian cancer, fallopian tube cancer, or primary peritoneal cancer: a phase II trial (ChiCTR2400090496)
    P2, N=132, Recruiting, Sun Yat-sen University Cancer Center; Sun Yat-sen University Cancer Center
    New P2 trial • Metastases
    |
    carboplatin • paclitaxel • Yidafan (ivonescimab)
    1m
    Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov)
    P1, N=18, Recruiting, University of Washington | Trial primary completion date: Sep 2024 --> Dec 2025
    Trial primary completion date • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset)
    |
    BRCA2 mutation • BRCA1 mutation
    |
    UW-Oncoplex™
    |
    Zejula (niraparib) • Jemperli (dostarlimab-gxly)
    1m
    STRO-002-GM2: A Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian Cancer (clinicaltrials.gov)
    P1, N=58, Recruiting, Sutro Biopharma, Inc. | Active, not recruiting --> Recruiting
    Enrollment open • Combination therapy • Metastases
    |
    Avastin (bevacizumab) • luveltamab tazevibulin (STRO-002)
    1m
    LYL797-101: A Study to Investigate LYL797 in Adults With Solid Tumors (clinicaltrials.gov)
    P1, N=100, Active, not recruiting, Lyell Immunopharma, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed • CAR T-Cell Therapy
    |
    ROR1 (Receptor Tyrosine Kinase Like Orphan Receptor 1)
    |
    LYL797
    1m
    A Post-marketing Surveillance to Assess the Safety and Effectiveness of Zirabev in Domestic Patients With Various Cancer (clinicaltrials.gov)
    P=N/A, N=400, Not yet recruiting, Pfizer | Trial completion date: May 2025 --> Aug 2025 | Trial primary completion date: May 2025 --> Aug 2025
    Trial completion date • Trial primary completion date • Metastases
    |
    Zirabev (bevacizumab-bvzr)
    1m
    EFFORT: Adavosertib with or Without Olaparib in Treating Patients with Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (clinicaltrials.gov)
    P2, N=104, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    HRD (Homologous Recombination Deficiency) • BRCA (Breast cancer early onset)
    |
    HRD • BRCA mutation
    |
    Lynparza (olaparib) • adavosertib (AZD1775) • ceralasertib (AZD6738)
    2ms
    Study of Maplirpacept (PF-07901801) in Combination With PLD in Patients With Platinum-Resistant Ovarian Cancer (clinicaltrials.gov)
    P2, N=10, Terminated, Pfizer | Phase classification: P1/2 --> P2
    Phase classification • Combination therapy
    |
    pegylated liposomal doxorubicin • maplirpacept (TTI-622)
    2ms
    A Phase II Study Of Nivolumab/ Bevacizumab/Rucaparib (clinicaltrials.gov)
    P2, N=73, Active, not recruiting, Dana-Farber Cancer Institute | Trial completion date: Oct 2026 --> Jan 2027 | Trial primary completion date: Oct 2024 --> Jan 2025
    Trial completion date • Trial primary completion date • Combination therapy
    |
    BRCA (Breast cancer early onset)
    |
    BRCA mutation
    |
    Opdivo (nivolumab) • Avastin (bevacizumab) • Rubraca (rucaparib)